Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Pharmacologic resistance in colorectal cancer: a review
- William A. Hammond, A. Swaika, K. Mody
- Therapeutic advances in medical oncology
- 1 January 2016
The current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC are discussed. Expand
Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution
LPD provides similar short-term outcomes and long-term survival to OPD in the treatment of PDAC, and is associated with larger tumor size; LPD was associated with greater lymph node harvest and lower lymph node ratio. Expand
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Purpose: To analytically and clinically validate microsatellite instability (MSI) detection using cell-free DNA (cfDNA) sequencing. Experimental Design: Pan-cancer MSI detection using Guardant360 was… Expand
Antiangiogenic Therapy in Colorectal Cancer
The data supporting the use of antiangiogenics in this disease are reviewed and bevacizumab is reviewed, the only anti-angiogenic agent approved by the US Food and Drug Administration for first-line treatment of metastatic colorectal cancer. Expand
Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Adenocarcinoma
LDP is associated with less blood loss and need for blood transfusion, shorter hospital stay, and faster time to initiate adjuvant therapy than ODP for patients with PDAC; postoperative outcomes and long-term survival are similar between the two groups. Expand
Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations.
The results suggest molecular heterogeneity among epithelial tumors of the appendix and next generation sequencing efforts have identified mutational spectra in several subtypes of these tumors that may suggest a phenotypic heterogeneity showing mutations that are relevant for targeted therapies. Expand
Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers
PURPOSERecent advances in molecular diagnostic technologies have allowed for the evaluation of solid tumor malignancies via noninvasive blood sampling, including circulating tumor DNA (ctDNA) profi...
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).
This data indicates that in metastatic colorectal cancer with deficient DNA mismatch repair (dMMR), anti-PD-1 antibody monotherapy produced high tumor response rates and extended progression-free survival in mice treated with this drug. Expand
Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC,…
In metastatic colorectal cancer with deficient DNA mismatch repair (MMR), anti-PD-1 antibody monotherapy produced high tumor response rates and extended progression-free survival in mice treated with this drug. Expand